您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Dian Zhou1,2, Ying Wang1,2, Chong Chen1,2
1Department of Hematology, Affiliated Hospital of Xuzhou Medical University, #99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China.
G蛋白结合受体类C组5成员D (GPRC5D) 是多发性骨髓瘤 (MM) 的一个有前途的免疫治疗点. 研究正在探索针对GPRC5D的治疗方法,如针对复发性/耐药性MM的双特异性抗体和CAR T细胞.
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: